Million Women Study
Jump to navigation
Jump to search
Introduction
Study characteristics:
- 700,000 women mean age 58
grouped according to hormone replacement therapy (HRT)
- estrogen alone
- estrogen combined with continuous progesterone
- estrogen combined with cyclic progesterone
- none
Results: (3.4 years duration)
- relative risk of endometrial cancer with HRT vs none
- estrogen alone (1.45)
- estrogen combined with continuous progesterone (0.71)
- estrogen combined with cyclic progesterone (1.05)
- relative risk of endometrial conacer for obese vs non obese women = 4.0 (no HRT)
- among obese women, continuous & cyclic HRT reduced risk or endometrial cancer
Conclusions:
- Since breast cancer is much more common than endometrial cancer, the increase risk of breast cancer with HRT outweighs any reduction in endometrial cancer
More general terms
Additional terms
- breast cancer
- endometrial cancer (carcinoma)
- hormone replacement therapy (HRT); estrogen replacement therapy; postmenopausal hormone replacement therapy
References
- ↑ Journal Watch 25(13):108, 2005 Beral V, Bull D, Reeves G; Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005 Apr 30-May 6;365(9470):1543-51. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15866308